TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26226244

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (DCC), clamped 120 seconds after delivery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (DCC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early umbilical cord clamping (ECC), clamped <10 seconds after birth
Number of subjects: 30
Study: 23047118

Group type: EXPERIMENTAL
Intervention: GS-9451 60 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GS-9451 200 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GS-9451 400 mg/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GS-9451 200 mg/day (genotype 1b)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 19763813

Group type: EXPERIMENTAL
Intervention: Couples' voluntary counseling and testing (CVCT)
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Individual voluntary counseling and testing (IVCT)
Number of subjects: 1521
Study: 18466075

Group type: EXPERIMENTAL
Intervention: Famotidine (1 week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esomeprazole (1 week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ezetimibe (single dose with levothyroxine)
Number of subjects: 30
Study: 16567981

Group type: EXPERIMENTAL
Intervention: MMR with PCV7
Number of subjects: 694

Group type: COMPARATOR
Intervention: MMR without PCV7
Number of subjects: 694
Study: 12696630

Group type: EXPERIMENTAL
Intervention: DSCG-chlorpheniramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 10
Study: 11090557

Group type: EXPERIMENTAL
Intervention: 0.9% IV saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.45% IV saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.45% oral saline
Number of subjects: 8

Group type: COMPARATOR
Intervention: No rehydration treatment
Number of subjects: 8
Study: 8937491

Group type: EXPERIMENTAL
Intervention: Single administration of DMDC at 200 mg/m2 (initial dose) increased to 450 mg/m2.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single repeated administration of DMDC at 300 mg/m2.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5-consecutive-day administration of DMDC starting at 30 mg/m2/day increased to 40 mg/m2/day.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All administration schedules of DMDC.
Number of subjects: 28
Study: 1530174

Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms), followed by an infusion of 18.75 micrograms/h
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study: 3888116

Group type: EXPERIMENTAL
Intervention: MCNU
Number of subjects: 95

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 95
Study: 30679141

Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography (STE) analysis in DMD group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Conventional echocardiographic measures
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Age effect on global LV longitudinal strain
Number of subjects: 108

Group type: COMPARATOR
Intervention: Right ventricular function
Number of subjects: 108
Study: 30602630

Group type: EXPERIMENTAL
Intervention: Toothpaste (TP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mouthwash (MW)
Number of subjects: 60
Study: 27083443

Group type: EXPERIMENTAL
Intervention: Panitumumab with FOLFOX4
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Panitumumab with FOLFIRI
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Panitumumab with best supportive care
Number of subjects: 951

Group type: COMPARATOR
Intervention: Worst skin toxicity grade <3
Number of subjects: 951

Group type: COMPARATOR
Intervention: Worst skin toxicity grade ≥3
Number of subjects: 951
Study: 24870697

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HFM (high-energy, high-fat meal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HFM
Number of subjects: 10
Study: 22103692

Group type: EXPERIMENTAL
Intervention: Reasons for living themes identified from qualitative interviews
Number of subjects: 36
Study: 20513886

Group type: EXPERIMENTAL
Intervention: Lateral subvastus approach with tibial tubercle osteotomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 32
Study: 17673455

Group type: EXPERIMENTAL
Intervention: Frozen sperm from cryptozoospermic patients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fresh sperm from cryptozoospermic patients
Number of subjects: 116

Group type: COMPARATOR
Intervention: Fresh sperm from control group (normal patients >10(5) spermatozoa/ml)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fresh sperm from oligospermic patients
Number of subjects: 116
Study: 15876629

Group type: EXPERIMENTAL
Intervention: Fractal analysis of body motion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy elderly subjects
Number of subjects: 0
Study: 11192874

Group type: EXPERIMENTAL
Intervention: ABT‐378 200 mg with ritonavir 100 mg every 12 h plus stavudine 40 mg and lamivudine 150 mg every 12 h (group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ABT‐378 400 mg with ritonavir 100 or 200 mg plus stavudine and lamivudine every 12 h (group II)
Number of subjects: 100
Study: 9626825

Group type: EXPERIMENTAL
Intervention: Hirudin (adjunctive therapy)
Number of subjects: 3289

Group type: COMPARATOR
Intervention: Heparin (adjunctive therapy)
Number of subjects: 3289
Study: 8066221

Group type: EXPERIMENTAL
Intervention: Gamete intrafallopian transfer (GIFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro fertilization (IVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdrop insemination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subzonal sperm microinjection (SUSM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate transfer of SUSM oocytes to the Fallopian tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct microinjection of epididymal sperm from azoospermic men
Number of subjects: 0
Study: 3057956

Group type: EXPERIMENTAL
Intervention: Supplementary oral nutrition for 3 months (Group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Normal diet for 9 months (Group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal diet for 9 months (Group 3 - Control)
Number of subjects: 14
Study: 29463619

Group type: EXPERIMENTAL
Intervention: Direct aspiration first pass (ADAPT) approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stent retriever as the first-line (SRFL) approach
Number of subjects: 0
Study: 28734660

Group type: EXPERIMENTAL
Intervention: CAN/AML combination therapy (8 mg/5 mg)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: CAN/AML combination therapy (16 mg/5 mg)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: CAN/AML combination therapy (16 mg/10 mg)
Number of subjects: 425

Group type: COMPARATOR
Intervention: CAN (8 mg)
Number of subjects: 425

Group type: COMPARATOR
Intervention: AML (10 mg)
Number of subjects: 425

Group type: COMPARATOR
Intervention: AML (5 mg)
Number of subjects: 425
Study: 26239766

Group type: EXPERIMENTAL
Intervention: Pramipexole (titrated up to 3.0mg/d over 15 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23477485

Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 123
Study: 21368745

Group type: EXPERIMENTAL
Intervention: Fresolimumab (up to 4 mg/kg)
Number of subjects: 16
Study: 19047525

Group type: EXPERIMENTAL
Intervention: Baseline depression defined as a Center for Epidemiological Studies Depression score of 16 or higher
Number of subjects: 2088
Study: 17725138

Group type: EXPERIMENTAL
Intervention: Early feeding (liquid diet within 8 hours, soft diet next meal, regular diet thereafter)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional feeding (no mouth feeding for first 24 hours, liquid diet on first postoperative day, soft diet on second postoperative day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional feeding
Number of subjects: 200
Study: 14571754

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg every 12 h
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravenous cefotaxime 2 g every 8 h
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 2 g every 24 h
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 53
Study: 16202717

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering diet from gestational week 17 to 20 to birth
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 290
Study: 10599355

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 7492038

Group type: EXPERIMENTAL
Intervention: Adenosine as a standing-order medication
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (historical controls from 1992)
Number of subjects: 239
Study: 1664617

Group type: EXPERIMENTAL
Intervention: Maprotyline
Number of subjects: 93

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 93
Study: 7021071

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1600 mg, 400 mg every 6 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28662676

Group type: COMPARATOR
Intervention: Yogurt smoothie with no BB‐12® (YS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB‐12® added pre‐fermentation (PRE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB‐12® added post‐fermentation (POST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BB‐12® containing capsule (CAP)
Number of subjects: 30
Study: 25037968

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied from the first day of the conditioning regimen until day 7 post-HSCT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 30
Study: 23895803

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 4330

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 4330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4330
Study: 20942831

Group type: EXPERIMENTAL
Intervention: bevacizumab + interferon-α2a (IFN)
Number of subjects: 649

Group type: COMPARATOR
Intervention: IFN + placebo
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: bevacizumab + IFN (censored for TKIs)
Number of subjects: 649

Group type: COMPARATOR
Intervention: IFN + placebo (censored for TKIs)
Number of subjects: 649
Study: 19364976

Group type: EXPERIMENTAL
Intervention: 1 portion of fruit and vegetables daily
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 3 portions of fruit and vegetables daily
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 6 portions of fruit and vegetables daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (1 portion per day during run-in)
Number of subjects: 117
Study: 17485711

Group type: EXPERIMENTAL
Intervention: SLND + ALND
Number of subjects: 891

Group type: COMPARATOR
Intervention: SLND alone
Number of subjects: 891
Study: 15598756

Group type: EXPERIMENTAL
Intervention: Advice from any health care professional
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Multiprovider teams
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dentists
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study: 11464225

Group type: EXPERIMENTAL
Intervention: 3 mg elemental Cu/day as CuSO4
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6 mg elemental Cu/day as CuSO4
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9579817

Group type: EXPERIMENTAL
Intervention: Patients with isolated aortic stenosis (AS)
Number of subjects: 39
Study: 7995323

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with piretanide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment with ramipril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of ramipril and piretanide
Number of subjects: 24
Study: 3376144

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 ml/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31364885

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study: 30665722

Group type: EXPERIMENTAL
Intervention: CVT-301 (levodopa inhalation powder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29143588

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25873249

Group type: EXPERIMENTAL
Intervention: Minimally invasive total gastrectomy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 168
Study: 24061990

Group type: EXPERIMENTAL
Intervention: IMRT-TP (Intensity-Modulated Radiation Therapy plus chemotherapy with docetaxel and cisplatin)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: IMRT-TP
Number of subjects: 170

Group type: COMPARATOR
Intervention: IMRT (Simple Intensity-Modulated Radiation Therapy)
Number of subjects: 170
Study: 21960694

Group type: EXPERIMENTAL
Intervention: Common polymorphisms in ADIPOQ (rs266729, rs182052, rs822391, rs2082940)
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Common polymorphisms in ADIPOQ (rs266729, rs182052, rs16861209, rs17366568, rs3774261, rs7639352)
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Common polymorphisms in ADIPOQ (rs1686109, rs17366568, rs3774261)
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Common polymorphism in ADIPOQ (rs16861205)
Number of subjects: 2553

Group type: COMPARATOR
Intervention: 16 variants in ADIPOR1/R2
Number of subjects: 2553
Study: 21110393

Group type: EXPERIMENTAL
Intervention: Judicial directions provided before the child complainant testified
Number of subjects: 130

Group type: COMPARATOR
Intervention: Endorsement of CSA misconceptions
Number of subjects: 130
Study: 18265636

Group type: EXPERIMENTAL
Intervention: Upper abdominal surgery (transversal laparotomy, elliptic periumbilical laparotomy, upper midline laparotomy, transrectal laparotomy, subcostal laparotomy)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low abdominal surgery (low midline laparotomy, inguinal incision)
Number of subjects: 105
Study: 15996667

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion with arithmetic increase
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion with geometric increase
Number of subjects: 120
Study: 12086732

Group type: EXPERIMENTAL
Intervention: Sustained release Ibifen (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Orudis retard (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prompt release Ibifen (100 mg, two 12-h doses)
Number of subjects: 12
Study: 9864078

Group type: EXPERIMENTAL
Intervention: Gabapentin (mean daily dose: 3,646.15 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8666093

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose, followed by 200 mg o.d.)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Amoxycillin-clavulanic acid (500/125 mg t.i.d.)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Erythromycin (1 g b.i.d.)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 808

Group type: COMPARATOR
Intervention: Amoxycillin-clavulanic acid
Number of subjects: 808

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 808
Study: 2355095

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Meridol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 374454

Group type: EXPERIMENTAL
Intervention: Lactose-free (LF) drink
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lactose-containing (LC) drink (4.5% lactose)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Breath hydrogen analysis
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Absorbers and malabsorbers
Number of subjects: 87
Study: 31647257

Group type: EXPERIMENTAL
Intervention: Family interaction tasks (3 increasingly conflictual tasks)
Number of subjects: 458
Study: 30767826

Group type: EXPERIMENTAL
Intervention: High-Intensity Treatment (HIT)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Low-Intensity Treatment (LIT)
Number of subjects: 686
Study: 28498975

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 325
Study: 25691671

Group type: EXPERIMENTAL
Intervention: ET-B (bevacizumab 15 mg/kg every 3 weeks + endocrine therapy)
Number of subjects: 374

Group type: COMPARATOR
Intervention: ET (letrozole or fulvestrant)
Number of subjects: 374
Study: 23888538

Group type: EXPERIMENTAL
Intervention: Online coaching programme
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 21453880

Group type: EXPERIMENTAL
Intervention: Probio‐Tec AB‐25 (Lactobacillus acidophilus La‐5 and Bifidobacterium animalis subsp. lactis BB‐12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Probio‐Tec AB‐25
Number of subjects: 32
Study: 19661810

Group type: EXPERIMENTAL
Intervention: HPV-16 therapeutic vaccine
Number of subjects: 35
Study: 16729400

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Both nitroglycerin and nitroprusside
Number of subjects: 379
Study: 14765636

Group type: EXPERIMENTAL
Intervention: Argon laser (250 mW for 10 seconds)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical fluoride (0.5% fluoride ion) followed by argon laser
Number of subjects: 5

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 5
Study: 11552048

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 50 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dipyridamole (sustained-release preparation 400 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of ASA and dipyridamole
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9245879

Group type: EXPERIMENTAL
Intervention: High resolution ultrasound
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 84

Group type: COMPARATOR
Intervention: Histology
Number of subjects: 84
Study: 8471228

Group type: EXPERIMENTAL
Intervention: Intravenous rHuEPO (IV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO (SC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND)
Number of subjects: 50
Study: 3612782

Group type: EXPERIMENTAL
Intervention: Continuous coronary heart disease (CHD) risk-factor intervention program (SI group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No intervention (UC group)
Number of subjects: 220
Study: 29910056

Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (allo‐MSCs) via 20 transendocardial injections
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle (placebo) via 20 transendocardial injections
Number of subjects: 36
Study: 26831919

Group type: EXPERIMENTAL
Intervention: CAD/CAM zirconia abutments with cemented lithium disilicate crowns
Number of subjects: 110
Study: 24733462

Group type: EXPERIMENTAL
Intervention: BMS-791325 (100, 300, 600, or 900 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BMS-791325 (900 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22971555

Group type: EXPERIMENTAL
Intervention: F+R (feedback of activity counts + reinforcement for physical activity by providing access to television)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: F+R
Number of subjects: 61

Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study: 20466313

Group type: EXPERIMENTAL
Intervention: RCTs published in the Journal of Dental Research (high impact factor journal)
Number of subjects: 163

Group type: COMPARATOR
Intervention: RCTs published in other journals (European Journal of Oral Sciences, Journal of Dentistry, Clinical Oral Investigations)
Number of subjects: 163
Study: 17900584

Group type: EXPERIMENTAL
Intervention: Infracoccygeal sacropexy (IS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sacrospinous suspension (SS)
Number of subjects: 49
Study: 15365074

Group type: EXPERIMENTAL
Intervention: Irinotecan plus gemcitabine (IRINOGEM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (GEM)
Number of subjects: 180
Study: 11384790

Group type: EXPERIMENTAL
Intervention: Workshop strategies to enhance adherence and retention
Number of subjects: 0
Study: 9648993

Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis (n=61)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Patients with Crohn's disease (n=76)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Relatives of patients with ulcerative colitis (n=101)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Relatives of patients with Crohn's disease (n=105)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Healthy unrelated controls (n=56)
Number of subjects: 339
Study: 7719261

Group type: EXPERIMENTAL
Intervention: Berodual
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ipratropium Bromide
Number of subjects: 59